...
首页> 外文期刊>Journal of Applied Genetics >Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
【24h】

Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing

机译:134例连续性卵巢癌患者中BRCA1 / 2的突变分析。下一代测序检测到的新型和复发性BRCA1 / 2改变

获取原文
获取原文并翻译 | 示例
           

摘要

The importance of proper mutational analysis of BRCA1/2 in individuals at risk for hereditary breast and ovarian cancer syndrome is widely accepted. Standard genetic screening includes targeted analysis of recurrent, population-specific mutations. The purpose of the study was to establish the frequency of germline BRCA1/2 mutations in a group of 134 unrelated patients with primary ovarian cancer. Next generation sequencing analysis revealed a presence of 20 (14.9 %) mutations, where 65 % (n = 13) were recurrent BRCA1 alterations included in the standard diagnostic panel in northern Poland. However, the remaining seven BRCA1/2 mutations (35 %) would be missed by the standard approach and were detected in unique patients. A substantial proportion (n = 5/12; 41 %) of mutation-positive individuals with complete family history reported no incidence of breast or ovarian cancer in their relatives. This observation, together with the raising perspectives for personalized therapy targeting BRCA1/2 signaling pathways indicates the necessity of comprehensive genetic screening in all ovarian cancer patients. However, due to the limited sensitivity of the standard genetic screening presented in this study (65 %) an application of next generation sequencing in molecular diagnostics of BRCA1/2 genes should be considered.
机译:在有遗传性乳腺癌和卵巢癌综合症风险的个体中进行BRCA1 / 2正确突变分析的重要性已被广泛接受。标准的基因筛查包括针对复发的人群特异性突变的靶向分析。该研究的目的是确定134例原发性卵巢癌无关患者中生殖细胞BRCA1 / 2突变的频率。下一代测序分析显示存在20(14.9%)突变,其中65%(n = 13)是波兰北部标准诊断小组中包括的复发性BRCA1改变。但是,标准方法会遗漏其余七个BRCA1 / 2突变(35%),并在独特的患者中检测到。具有完整家族史的突变阳性个体中有相当一部分(n = 5/12; 41%)报告其亲属中没有乳腺癌或卵巢癌的发病率。该观察结果以及针对BRCA1 / 2信号通路的个性化治疗方法的发展前景表明,在所有卵巢癌患者中进行全面基因筛查是必要的。然而,由于这项研究中提出的标准基因筛选的敏感性有限(65%),因此应考虑将下一代测序技术应用于BRCA1 / 2基因的分子诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号